Literature DB >> 32691539

Feasibility Study of Synthetic Diffusion-Weighted MRI in Patients with Breast Cancer in Comparison with Conventional Diffusion-Weighted MRI.

Bo Hwa Choi1,2, Hye Jin Baek3, Ji Young Ha1, Kyeong Hwa Ryu1, Jin Il Moon1, Sung Eun Park1, Kyungsoo Bae1, Kyung Nyeo Jeon1, Eun Jung Jung4.   

Abstract

OBJECTIVE: To investigate the clinical feasibility of synthetic diffusion-weighted imaging (sDWI) at different b-values in patients with breast cancer by assessing the diagnostic image quality and the quantitative measurements compared with conventional diffusion-weighted imaging (cDWI).
MATERIALS AND METHODS: Fifty patients with breast cancer were assessed using cDWI at b-values of 800 and 1500 s/mm² (cDWI800 and cDWI1500) and sDWI at b-values of 1000 and 1500 s/mm² (sDWI1000 and sDWI1500). Qualitative analysis (normal glandular tissue suppression, overall image quality, and lesion conspicuity) was performed using a 4-point Likert-scale for all DWI sets and the cancer detection rate (CDR) was calculated. We also evaluated cancer-to-parenchyma contrast ratios for each DWI set in 45 patients with the lesion identified on any of the DWI sets. Statistical comparisons were performed using Friedman test, one-way analysis of variance, and Cochran's Q test.
RESULTS: All parameters of qualitative analysis, cancer-to-parenchyma contrast ratios, and CDR increased with increasing b-values, regardless of the type of imaging (synthetic or conventional) (p < 0.001). Additionally, sDWI1500 provided better lesion conspicuity than cDWI1500 (3.52 ± 0.92 vs. 3.39 ± 0.90, p < 0.05). Although cDWI1500 showed better normal glandular tissue suppression and overall image quality than sDWI1500 (3.66 ± 0.78 and 3.73 ± 0.62 vs. 3.32 ± 0.90 and 3.35 ± 0.81, respectively; p < 0.05), there was no significant difference in their CDR (90.0%). Cancer-to-parenchyma contrast ratios were greater in sDWI1500 than in cDWI1500 (0.63 ± 0.17 vs. 0.55 ± 0.18, p < 0.001).
CONCLUSION: sDWI1500 can be feasible for evaluating breast cancers in clinical practice. It provides higher tumor conspicuity, better cancer-to-parenchyma contrast ratio, and comparable CDR when compared with cDWI1500.
Copyright © 2020 The Korean Society of Radiology.

Entities:  

Keywords:  Breast cancer; Diffusion-weighted imaging; MRI; Synthetic MRI; b-value

Mesh:

Year:  2020        PMID: 32691539      PMCID: PMC7371621          DOI: 10.3348/kjr.2019.0568

Source DB:  PubMed          Journal:  Korean J Radiol        ISSN: 1229-6929            Impact factor:   3.500


INTRODUCTION

Magnetic resonance imaging (MRI) is widely used for evaluating breast cancer due to its high sensitivity, which can be attributed to its excellent soft-tissue contrast (1). However, breast MRI is a time-consuming modality, as it requires acquisition of multiple sequences. Recently, abbreviated breast MRI protocol was introduced to overcome this issue. However, this technique uses contrast media that can result in unexpected adverse effects (2). In clinical practice, diffusion-weighted imaging (DWI) may be an alternative approach for evaluating breast lesions, as contrast agents are not required, and images can be obtained rapidly. Several studies have reported the potential value of DWI as a non-contrast imaging modality in breast cancer detection (3456). Although the image quality of DWI and apparent diffusion coefficient (ADC) maps are affected by b-value selection, the optimal b-value in breast imaging remains debatable. A large b-value (> 1000 s/mm2) reflects stronger diffusion-weighting, which suppresses benign and normal tissue and enables detection of cancers (7). However, the limitations of DWI using a high b-value include prolonged acquisition time and low signal-to-noise ratios (SNRs) due to requirement of longer echo times (TEs) and artifacts such as eddy current-induced distortions (8). In contrast to conventional DWI (cDWI), synthetic DWI (sDWI) is mathematically derived from directly acquired DWI with at least two different b-values (8). This approach may overcome the limitations of cDWI by achieving background suppression of a very high b-value DWI without additional acquisition scan time. Recent studies have reported the clinical usefulness of sDWI in detection of whole-body malignant tumors, hepatic metastases, prostate cancers, cervical cancers, and pancreatic cancers (8910111213141516171819202122). To date, few studies have focused on sDWI in breast imaging and have demonstrated excellent lesion conspicuity by suppressing the background signal intensity (SI) in sDWI with high b-values, with consequent improvement in the sensitivity for detection of cancerous lesions (232425). However, previous studies did not quantitatively evaluate sDWI and cDWI in patients with breast cancer. Therefore, this study aimed to investigate the clinical feasibility of sDWI at different b-values in patients with breast cancer by qualitative and quantitative assessment compared with cDWI.

MATERIALS AND METHODS

Patient Population

The present study involved retrospective analysis of prospectively acquired data. It was approved by our Institutional Review Board and the need to obtain informed consent was waived. We searched for picture archiving and communication system (PACS) reports. From September 2017 to July 2019, 69 female patients with biopsy-proven breast cancers who underwent preoperative breast 3T MRI were enrolled. We focused on the comparison of sDWI and cDWI with high b-values for detecting breast cancers. Therefore, we selected patients who underwent cDWI at b-values of 800 and 1500 s/mm2 (cDWI800 and cDWI1500). We excluded patients who did not undergo cDWI1500 (n = 18) and images with poor quality (n = 1). Finally, 50 patients were included in this study (median age, 52.5 years; range, 27–78 years). Histopathological diagnosis was established by ultrasound-guided core needle biopsy (n = 49) or stereotactic biopsy (n = 1). Characteristics of the patients and breast cancers are shown in Table 1. Among the 50 lesions, 41 were surgically removed at our institution. The average size of the lesions measured on pathological specimens was 29.8 ± 19.7 mm (range: 6–100 mm). Nine patients underwent surgery at another hospital. Therefore, we could not measure the pathological size of the lesions in these patients. The histopathological diagnoses included 39 invasive carcinomas and 11 ductal carcinomas in situ. The median interval between MRI and surgery was 7 days (range, 1–37 days).
Table 1

Characteristics of 50 Women with Histopathologically-Proven Breast Cancer

Clinical, Radiological and Histopathological CharacteristicsWomen with Breast Cancer (n = 50)
Patient age, median (range) (years)52.5 (27–78)
Amount of fibroglandular tissue, no. (%) of patients
 a2 (4.0)
 b5 (10.0)
 c35 (70.0)
 d8 (16.0)
Background parenchymal enhancement, no. (%) of patients
 Minimal29 (58.0)
 Mild13 (26.0)
 Moderate4 (8.0)
 Marked4 (8.0)
Menopausal status
 Premenopausal21 (42.0)
 Postmenopausal29 (58.0)
Histopathological subtype, no. (%) of cancer
 Invasive carcinoma of no special type28 (56.0)
 Invasive carcinoma with medullary feature5 (10.0)
 ILC2 (4.0)
 Mucinous carcinoma2 (4.0)
 Tubular carcinoma1 (2.0)
 Papillary carcinoma1 (2.0)
 DCIS11 (22.0)
Stage of cancer, no. (%) of patients (n = 41)*
 DCIS9 (22.0)
 Invasive, stage I16 (39.0)
 Invasive, stage II7 (17.1)
 Invasive, stage III8 (19.5)
 Invasive, stage IV1 (2.4)

*Of 50 lesions, 41 were surgically removed. DCIS = ductal carcinoma in situ, ILC = invasive lobular carcinoma

Image Acquisition

Breast MRI was performed using a 3T system (Architect, GE Healthcare, Milwaukee, WI, USA) with an 8-channel breast coil in prone position. The following MRI sequences were acquired: 1) 3-dimensional (3D) axial Dixon-based fat-suppressed T2-weighted fast-spin-echo sequence, 2) dynamic contrast-enhanced (DCE) high temporal and spatial resolution 3D T1-weighted sequence (Differential Subsampling with Cartesian Ordering) with dual-echo 3D spoiled gradient echo sequence with Dixon fat-water separation methods, 3) echo-planar imaging (EPI)-based cDWI with b-values of 100 and 800 s/mm2 (repetition time [TR], 3920 ms; TE, 70.9 ms; number of excitations [NEX], 2 and 6; and acquisition time, 3 minutes 16 seconds) and b-value of 1500 s/mm2 (TR, 4131 ms; TE, 82.5 ms; NEX, 2 and 6; and acquisition time, 2 minutes 27 seconds). Other parameters were identical between the two b-value acquisitions (section thickness, 5.0 mm; interslice gap, 0.5 mm; slice number, 38; field of view, 340 × 272 mm; and matrix, 128 × 128). The diffusion gradients were applied equally along the read, slice, and phase orthogonal directions. The TEs were set to minimum and were different for different b-values. An inversion preparation pulse with inversion time of 248 ms was applied to reduce fat. To synthesize DWI at b-values of 1000 and 1500 s/mm2 (sDWI1000 and sDWI1500), the following procedure was performed pixel by pixel. The signals of the acquired DWI at b-values of 100 and 800 s/mm2 were converted to the logarithmic scale and ADC was calculated using a linear least square fitting of the logged signals. Subsequently, the logged signal at b-values of 1000 or 1500 s/mm2 was calculated by extrapolation of the ADC fitted curve and converted to the final signal at b-values of 1000 or 1500 s/mm2. The sDWI data were reconstructed using commercially available software MAGiC DWI on a 64-bit Advantage Workstation (GE Healthcare). No errors were logged during processing and the average processing time was approximately under 5 seconds per case. The specific parameters of other sequences and contrast medium administration for MRI are described in the Supplementary Materials.

Image Analyses

For qualitative analysis, all data sets were anonymized by randomization and two readers reviewed all the images using PACS. Two readers with 4 years of experience in breast imaging and 2 years of fellowship performed independent analyses of all cDWI800, cDWI1500, sDWI1000, and sDWI1500 images to evaluate the quality from the perspective of diagnostic feasibility. Qualitative analysis of each image set was evaluated using the following items: 1) degree of normal glandular tissue suppression, 2) overall image quality, and 3) lesion conspicuity. The scoring was performed using a 4-point Likert scale. It was adapted from a study by Dogan et al. (Table 2) (26). For calculating the cancer detection rate (CDR), lesion conspicuity score 1 was considered a negative examination, while lesion conspicuity score ≥ 2 was considered a positive examination. The lesion identified by the reader had to match the pathological location of the index lesion in order to constitute a true-positive result.
Table 2

Scales for Qualitative Analysis

ScoreNormal Glandular Tissue SuppressionOverall Image QualityLesion Conspicuity
4Uniform throughout field of viewBestVery confidently assessed
3Inhomogeneity present, but not preventing assessmentFairConfidently assessed but slightly lack of delineation of lesion margin
2Inhomogeneity affects clinical assessmentPoorLesion present, features indeterminate
1Inhomogeneity prevents diagnostic evaluationNondiagnosticNondiagnostic
For quantitative analysis, two readers reviewed the information from all DWI sets of each patient and detected cancer with reference to the results of histopathological examination, T2-weighted images (T2WIs), and DCE T1-weighted images (DCE-MRI). The readers identified the index lesions on each DWI as a focal area of increased SI corresponding to the pathological location of the index lesion. Subsequently, a region of interest (ROI) was manually traced just within the outer margin of the identified abnormality on each image set, avoiding hemorrhage, necrosis, or cystic components. If no lesion could be identified on a given image set, an ROI was manually traced to correspond to the location of the identified lesion on other image sets. Five patients in whom the lesion could not be identified on any of the DWI sets were excluded from this quantitative analysis. For the remaining 45 patients, a small ROI was also traced in the normal glandular tissue of the contralateral breast, showing the densest normal breast parenchyma with homogeneous SI on all image sets as well as on T2WI. The mean value for each ROI was recorded. For each image set, cancer-to-parenchyma contrast ratio was calculated using the formula (SIG − SIcancer) / (SIG + SIcancer), where SIcancer and SIG were the average SIs for the cancer and normal glandular tissue, respectively (2728). ROI measurement was performed using a commercial workstation (AW Server 3.2, GE Healthcare). While assessing the SIs for cancer (mean size, 217 mm2; range, 27–768 mm2) and glandular tissue (mean size, 82 mm2; range, 6–240 mm2), the ROIs were first localized on cDWI1500. The size, shape, and location of the ROIs were kept constant for all DWI sets in each patient by applying the copy-and-paste function on the monitor.

Statistical Analyses

The data were tested for normal distribution with Kolmogorov-Smirnov test. Continuous variables were expressed as mean ± standard deviation (SD). The mean values of the readers' ratings in the qualitative analysis were not directly compared, as these values were not strictly continuous variables. However, we decided to present a summary for DWI sets, expressed as mean ± SD. The average scores from the two readers for each image set were calculated and compared using the Friedman test with post-hoc analysis. Cancer-to-parenchyma contrast ratios on each image set were compared using one-way analysis of variance and post-hoc Tukey's test. Cochran's Q Test was used to compare DWI sets in terms of CDR. A p-value < 0.05 was considered statistically significant. Interobserver agreement in qualitative analysis was compared by percent agreement. Intraclass correlation coefficient (ICC) with a two-way random model of consistency was used to investigate interobserver agreement in the quantitative analysis (29). All statistical analyses were performed using SPSS Statistics version 24.0 (IBM Corp., Armonk, NY, USA).

RESULTS

Qualitative and Quantitative Analyses: All DWI Sets

Table 3 shows the scores assigned by the two readers for the qualitative analyses of all image sets. There were significant differences in the scores for suppression of normal glandular tissue, overall image quality, and lesion conspicuity among the four sets. All these parameters showed a tendency to increase with increasing b-value (p < 0.001). In the post-hoc analysis for suppression of normal glandular tissue, sDWI1500 and cDWI1500 showed significantly higher scores than cDWI800 and sDWI1000 p < 0.001). cDWI1500 showed significantly higher scores for the overall image quality than other DWI sets p < 0.05). sDWI1500 and cDWI1500 showed significantly better lesion conspicuity than DWI sets with lower b-values p < 0.001), whereas comparison between sDWI1500 and cDWI1500 revealed no significant difference (p > 0.05). There was no significant difference in any of the parameters between sDWI1000 and cDWI800 in qualitative analysis. CDR was not significantly different among the four DWI sets (p = 0.061 for all cancers and p = 0.194 for invasive cancers) (Table 3).
Table 3

Comparative Results of Qualitative and Quantitative Analyses between cDWI800, sDWI1000, sDWI1500, and cDWI1500

ParameterscDWI800sDWI1000sDWI1500cDWI1500PP*PPP§
Suppression of normal glandular tissue2.34 ± 0.792.66 ± 0.783.32 ± 0.903.66 ± 0.78< 0.001< 0.001< 0.001< 0.001< 0.001
Overall image quality3.31 ± 0.883.33 ± 0.843.35 ± 0.813.73 ± 0.62< 0.001> 0.9990.002> 0.9990.002
Lesion conspicuity2.83 ± 0.963.09 ± 0.943.52 ± 0.923.39 ± 0.90< 0.001< 0.001< 0.001< 0.0010.051
CDR (invasive and in situ cancer), %84.0 (42/50)86.0 (43/50)90.0 (45/50)90.0 (45/50)0.061
CDR (invasive cancer), %89.7 (35/39)92.3 (36/39)94.9 (37/39)94.9 (37/39)0.194
Cancer-to-parenchyma contrast ratio0.47 ± 0.170.54 ± 0.160.63 ± 0.170.55 ± 0.18< 0.001< 0.0010.0090.0040.961

Pooled data from two readers are mean ± standard deviation. P values were calculated using Friedman test for qualitative anlaysis, Cochran's Q Test for CDR, and one-way ANOVA for cancer-to-parenchyma contrast ratio. *p values indicate comparisons between cDWI800 and sDWI1500 in post-hoc analysis, †p values indicate comparisons between cDWI800 and cDWI1500 in post-hoc analysis, ‡p values indicate comparisons between sDWI1000 and sDWI1500 in post-hoc analysis, §p values indicate comparisons between sDWI1000 and cDWI1500 in post-hoc analysis. CDR = cancer detection rate, cDWI800 = conventional low b-value (800 s/mm2) diffusion-weighted imaging, cDWI1500 = conventional high b-value (1500 s/mm2) diffusion-weighted imaging, sDWI1000 = synthetic high b-value (1000 s/mm2) diffusion-weighted imaging, sDWI1500 = synthetic high b-value (1500 s/mm2) diffusion-weighted imaging

In five patients (5/50), cancers could not be identified on any of the DWI sets. The histopathological diagnoses of these lesions included one tubular carcinoma (pathologic size: 1.2 cm), one invasive carcinoma of no special type (0.6 cm), and three ductal carcinomas in situ (1–2.8 cm). The cancer-to-parenchyma contrast ratios in the remaining 45 patients showed a significant difference among the four DWI sets p < 0.001). sDWI1500 revealed significantly higher cancer-to-parenchyma contrast ratios than the other DWI sets in the post-hoc analysis p < 0.05). Interobserver agreement of the cancer-to-parenchyma contrast ratios of all image sets was excellent (ICC: 0.887–0.960, p < 0.001).

Qualitative and Quantitative Analyses: cDWI1500 vs. sDWI1500

The two readers assigned a score of more than 3 points to all parameters on both cDWI1500 and sDWI1500, implying that both these sets were “fair for diagnostic use” (Table 4). The mean scores for suppression of normal glandular tissue and overall image quality were significantly higher in cDWI1500 than in sDWI1500 (reader 1, 3.56 and 3.86 vs. 3.14 and 3.42, respectively; and reader 2, 3.76 and 3.60 vs. 3.50 and 3.28, respectively; p < 0.05). However, lesion conspicuity scores were higher in sDWI1500 than in cDWI1500 (reader 1, 3.54 vs. 3.44, respectively; and reader 2, 3.50 vs. 3.34, respectively; p < 0.05). Fair to good interobserver agreement was observed in qualitative analysis of sDWI1500 and sDWI1500 (range: 44.0–72.0%).
Table 4

Comparative Results of Qualitative Analysis between cDWI1500 and sDWI1500

ParametersReaderscDWI1500Percent Agreement (%)sDWI1500Percent Agreement (%)P
Suppression of normal glandular tissue13.56 ± 0.9172.03.14 ± 0.9556.0< 0.001
23.76 ± 0.623.50 ± 0.81< 0.001
Overall image quality13.86 ± 0.5070.03.42 ± 0.7044.0< 0.001
23.60 ± 0.703.28 ± 0.900.002
Lesion conspicuity13.44 ± 0.9768.03.54 ± 0.9764.00.025
23.34 ± 0.823.50 ± 0.860.046

Data are mean ± standard deviation. P values were calculated using Wilcoxon signed rank test.

Both readers showed similar CDR values in sDWI1500 and cDWI1500 for all cancers (reader 1, 90.0% [45/50]; and reader 2, 94.0% [47/50]) and for invasive cancers (reader 1, 94.9% [37/39]; and reader 2, 100% [39/39]) (Table 5). DCE-MRI demonstrated the best CDR (for all cancers, reader 1 and 2, 96.0% [48/50] and for invasive cancers; reader 1 and 2, 100% [39/39]). However, there was no significant difference in CDR among sDWI1500, cDWI1500, and DCE-MRI (p ≥ 0.05).
Table 5

Comparison of CDR and Quantitative Analysis between cDWI1500 and sDWI1500

ParametersReaderscDWI1500 (%)sDWI1500 (%)DCE-MRI (%)P
CDR (invasive and in situ cancer)190.0 (45/50)90.0 (45/50)96.0 (48/50)0.050
294.0 (47/50)94.0 (47/50)96.0 (48/50)0.368
CDR (invasive cancer)194.9 (37/39)94.9 (37/39)100 (39/39)0.135
2100 (39/39)100 (39/39)100 (39/39)1.000
Cancer-to-parenchyma contrast ratio10.55 ± 0.180.62 ± 0.18NA< 0.001
20.55 ± 0.180.63 ± 0.17NA< 0.001

DCE-MRI = dynamic contrast-enhanced MRI, NA = not applicable

The cancer-to-parenchyma contrast ratios described by the two readers were significantly greater in sDWI1500 (0.62 ± 0.18 and 0.63 ± 0.17) than in cDWI1500 (0.55 ± 0.18 and 0.55 ± 0.18) p < 0.001). Representative cases are shown in Figure 1.
Fig. 1

49-year-old woman with 2.4 cm invasive ductal carcinoma (histologic grade 2) in right 3 o'clock position.

On conventional axial DWI at b-value of 800 s/mm2 (A) and on synthetic DWI at b-value of 1000 s/mm2 (B), breast cancer (arrows) shows hyperintensity, but border is obscured by insufficiently suppressed normal glandular tissue [suppression of normal glandular tissue: 2, image quality: 3, lesion conspicuity: 2, and cancer-to-parenchyma contrast ratios: 0.33 for (A) and 0.37 for (B)]. On synthetic DWI at b-value of 1500 s/mm2 (C), cancer (arrows) is clearly seen (suppression of normal glandular tissue: 3, image quality: 3, lesion conspicuity: 4, and cancer-to-parenchyma contrast ratio: 0.45) when compared with conventional DWI at b-value of 1500 s/mm2 (D) (suppression of normal glandular tissue: 3, image quality: 3, lesion conspicuity: 3, and cancer-to-parenchyma contrast ratio: 0.39). (E) Axial post-contrast subtraction image at same slice location demonstrates the enhancing tumor (arrow), showing similar lesion visibility on synthetic DWI at b-value of 1500 s/mm2. DWI = diffusion-weighted imaging

DISCUSSION

In the present study, sDWI provided better lesion conspicuity and cancer-to-parenchyma contrast ratios than cDWI at the same high b-value (1500 s/mm2). CDR values were comparable between these two sets. Although sDWI1500 showed inferior normal breast tissue suppression and overall image quality than cDWI1500, sDWI1500 yielded better scores in qualitative analysis than DWI sets with lower b-values. These results indicate that sDWI can be a feasible option for the diagnosis of breast cancer. Theoretically, an increase in the b-values should increase background suppression, resulting in better lesion conspicuity. Accordingly, suppression of glandular tissue, overall image quality, and lesion conspicuity improved in the present study with an increase in the b-value. Lesion conspicuity received the best score in sDWI1500. This could be explained by the higher cancer-to-parenchyma contrast ratio in sDWI1500 than in other DWI sets. This result is consistent with the results of previous studies involving malignancies of prostate, pancreas, and uterine cervix that demonstrated higher contrast ratios between the malignant tumor and the normal tissue on sDWI with increasing b-values (913162122). Recently, Bickel et al. (30) demonstrated changes in the parameters on sDWI at different b-values (1000–2000 s/mm2) in patients with breast cancer. They demonstrated a decrease in relative SNRs and contrast-to-noise ratios with increasing b-values, whereas cancer-to-parenchyma contrast ratios increased significantly (30). In the present study, cancer-to-parenchyma contrast ratios were greater in sDWI1500 than in cDWI1500. At a b-value of 1500 s/mm2, the SI of the background tissue began fading significantly, allowing better lesion conspicuity. However, the SI of cancer was also suppressed in cDWI. In contrast, the SI of cancer was not suppressed in sDWI, yielding higher cancer-to-parenchyma contrast ratios. Similar results have been reported in previous studies on pancreatic cancer (b-values: 1500 and 2000 s/mm2) and prostate cancer (b-value: 1500 s/mm2), showing better cancer-to-parenchyma contrast ratios in sDWI than in cDWI at the same b-value (913). In the current study, cDWI1500 and sDWI1500 showed better background suppression of normal tissue and comparable image quality when compared with DWI sets with lower b-values. This finding was consistent with the findings of previous studies on sDWI with high b-values (1500–2500 s/mm2) (2325). In addition, there was no significant difference in background suppression of normal tissue between cDWI1500 and sDWI1500. However, the image quality in sDWI1500 was inferior to that in cDWI1500. Lower readers' ratings for image quality on sDWI1500 might be attributed to the granular appearance of the image, which may be considered an inevitable artifact of synthetic images derived from ADC. Nevertheless, the granular appearance on sDWI did not interfere with the detection of cancers. Thus, the overall image quality of sDWI might be acceptable for clinical use. The image quality of DWI is affected by b-value selection. A previous meta-analysis recommended b-values of 0 and 1000 s/mm2 on 1.5T MRI for optimal differentiation between benign and malignant lesions (31). To date, there are no meta-analysis reports on the most appropriate b-value for 3T MRI. Moreover, detectability of breast cancer on DWI may be affected by patient-related factors. Hahn et al. (32) reported that detectability of invasive breast cancer on DWI was not influenced by background parenchymal enhancement, mammographic density, menopausal status, or menstrual cycle, but it was influenced by the degree of background signal suppression. However, Bickel et al. (30) reported that the preferred b-value on sDWI was commonly between 1200 and 1600 s/mm2 in the low breast density group and between 1400 and 1600 s/mm2 in the high breast density group. In the present study, insufficient suppression of normal fibroglandular tissue was commonly seen in younger premenopausal patients (median age < 52.5 years) with high breast density, which can result in failure to detect breast cancer on DWI. Considering these issues, optimal b-value may vary according to patient-related factors. However, obtaining images at multiple b-values is time-consuming. In this regard, sDWI can be a solution to overcome the limitations. sDWI using MAGiC DWI can provide synthetic images of comparable quality that can be acquired in 5 seconds, as opposed to 4–5 minutes for cDWI. However, further studies are needed to validate these claims, as several other software are available to generate sDWI. This study has some limitations that should be considered when interpreting the findings. This study was retrospective in nature, had a single-center design, and limited sample size. Breast MRI at our institution is mainly performed in patients with suspected breast cancer. Therefore, our sample selection was biased, considering the absence of other breast pathologies. All patients underwent MRI using a specific 3T scanner. Recent studies are exploring the application of DWI using various magnetic resonance scanners and software including different approaches to fat suppression or the readout-segmented EPI technique, which may affect the obtained images. Our analysis of cancer-to-parenchyma contrast ratios was based on assessment of the index lesion rather than the assessment of the complete tumor foci. Moreover, manual ROI selection was reader-dependent and small in size, which may have affected the results despite interobserver agreement. Relatively low cancer-to-parenchyma contrast ratios of DWI sets might be induced by the inhomogeneity of SI, which may have affected the results. We considered percent agreement to evaluate interobserver agreement instead of kappa statistics, as kappa statistics provide paradoxically low values due to imbalance in the number of concordant and discordant pairs (3334). In conclusion, sDWI1500 provided CDR comparable to cDWI1500 in patients with breast cancer. It also showed better lesion conspicuity and higher cancer-to-parenchyma contrast ratios than cDWI1500. Therefore, sDWI can be a feasible MRI option for screening or preoperative evaluation of patients with breast cancer due to its inherent benefits such as rapid scan time and reduced need for additional scanning or contrast agent. However, the overall image quality and background normal breast tissue suppression were inferior when compared with cDWI. Therefore, further technological efforts are essential to solve these issues and to expand the clinical use of sDWI in detecting breast cancer. We believe that further studies with larger sample sizes and various magnetic resonance scanners will validate our results.
  34 in total

1.  Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging.

Authors:  Hidetake Yabuuchi; Yoshio Matsuo; Shunya Sunami; Takeshi Kamitani; Satoshi Kawanami; Taro Setoguchi; Shuji Sakai; Masamitsu Hatakenaka; Makoto Kubo; Eriko Tokunaga; Hidetaka Yamamoto; Hiroshi Honda
Journal:  Eur Radiol       Date:  2010-07-18       Impact factor: 5.315

2.  Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T--initial experience.

Authors:  Masatoshi Hori; Tonsok Kim; Hiromitsu Onishi; Takashi Ueguchi; Mitsuaki Tatsumi; Atsushi Nakamoto; Takahiro Tsuboyama; Kaname Tomoda; Noriyuki Tomiyama
Journal:  Radiology       Date:  2010-11-02       Impact factor: 11.105

3.  Pelvic imaging using a T1W fat-suppressed three-dimensional dual echo Dixon technique at 3T.

Authors:  Daniel M Cornfeld; Gary Israel; Shirley M McCarthy; Jeffery C Weinreb
Journal:  J Magn Reson Imaging       Date:  2008-07       Impact factor: 4.813

4.  Computed diffusion-weighted MRI for prostate cancer detection: the influence of the combinations of b-values.

Authors:  Y Ueno; S Takahashi; Y Ohno; K Kitajima; M Yui; Y Kassai; F Kawakami; H Miyake; K Sugimura
Journal:  Br J Radiol       Date:  2015-01-21       Impact factor: 3.039

5.  Comparison of the Diagnostic Performance of Synthetic Versus Acquired High b-Value (1500 s/mm2 ) Diffusion-Weighted MRI in Women With Breast Cancers.

Authors:  Jung Hyun Park; Bo La Yun; Mijung Jang; Hye Shin Ahn; Sun Mi Kim; Soo Hyun Lee; Eunyoung Kang; Eun-Kyu Kim; So Yeon Park
Journal:  J Magn Reson Imaging       Date:  2018-08-21       Impact factor: 4.813

6.  Breast lesions detected on MR imaging: features and positive predictive value.

Authors:  Laura Liberman; Elizabeth A Morris; Melissa Joo-Young Lee; Jennifer B Kaplan; Linda R LaTrenta; Jennifer H Menell; Andrea F Abramson; Stephen M Dashnaw; Douglas J Ballon; D David Dershaw
Journal:  AJR Am J Roentgenol       Date:  2002-07       Impact factor: 3.959

7.  Computed diffusion-weighted MR imaging for visualization of pancreatic adenocarcinoma: Comparison with acquired diffusion-weighted imaging.

Authors:  Yoshihiko Fukukura; Yuichi Kumagae; Hiroto Hakamada; Toshikazu Shindo; Koji Takumi; Kiyoshisa Kamimura; Masanori Nakajo; Aya Umanodan; Takashi Yoshiura
Journal:  Eur J Radiol       Date:  2017-07-29       Impact factor: 3.528

8.  Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer.

Authors:  Kinzya B Grant; Harsh K Agarwal; Joanna H Shih; Marcelino Bernardo; Yuxi Pang; Dagane Daar; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Abdom Imaging       Date:  2015-03

9.  Meta-analysis of quantitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions.

Authors:  Xin Chen; Wen-ling Li; Yi-li Zhang; Qian Wu; You-min Guo; Zhi-lan Bai
Journal:  BMC Cancer       Date:  2010-12-29       Impact factor: 4.430

10.  Feasibility of Computed Diffusion Weighted Imaging and Optimization of b-value in Cervical Cancer.

Authors:  Yusaku Moribata; Aki Kido; Koji Fujimoto; Yuki Himoto; Yasuhisa Kurata; Fuki Shitano; Kayo Kiguchi; Ikuo Konishi; Kaori Togashi
Journal:  Magn Reson Med Sci       Date:  2016-09-16       Impact factor: 2.471

View more
  3 in total

1.  Clinical experience of tensor-valued diffusion encoding for microstructure imaging by diffusional variance decomposition in patients with breast cancer.

Authors:  Eun Cho; Hye Jin Baek; Filip Szczepankiewicz; Hyo Jung An; Eun Jung Jung; Ho-Joon Lee; Joonsung Lee; Sung-Min Gho
Journal:  Quant Imaging Med Surg       Date:  2022-03

2.  A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice.

Authors:  Laura Martincich; Katja Pinker; Roberto Lo Gullo; Varadan Sevilimedu; Pascal Baltzer; Denis Le Bihan; Julia Camps-Herrero; Paola Clauser; Fiona J Gilbert; Mami Iima; Ritse M Mann; Savannah C Partridge; Andrew Patterson; Eric E Sigmund; Sunitha Thakur; Fabienne E Thibault
Journal:  Eur Radiol       Date:  2022-05-04       Impact factor: 7.034

Review 3.  Diffusion Breast MRI: Current Standard and Emerging Techniques.

Authors:  Ashley M Mendez; Lauren K Fang; Claire H Meriwether; Summer J Batasin; Stéphane Loubrie; Ana E Rodríguez-Soto; Rebecca A Rakow-Penner
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.